[Treatment of primary cerebral lymphoma. General principles and results].
In the SFNC series (248 patients), extension of surgical resection provided no increase in survival (p = 0.04). One hundred and twenty nine patients (52.2%) receive chemotherapy in addition to radiation therapy; 60 patients (24.3%) received radiation therapy alone, and 35 patients (14.2%) chemotherapy alone. One hundred seventeen patients (48.3%) were in remission at the conclusion of the treatment. The median survival was 12 months. Actuarial survival rates for the 248 patients at 1, 2 and 5 years after diagnosis were 48%, 37% and 27%, respectively. Treatment method provided increase in survival, and radiation therapy in addition to chemotherapy significantly enhanced the duration of survival.
Bataille
B
B
Service de Neurochirurgie, CHU, Poitiers.
D000206:Actuarial Analysis; D000704:Analysis of Variance; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D002423:Cause of Death; D017024:Chemotherapy, Adjuvant; D005500:Follow-Up Studies; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D018714:Radiotherapy, Adjuvant; D012074:Remission Induction; D015996:Survival Rate; D016896:Treatment Outcome
D000970:Antineoplastic Agents